Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “TKI Resistance”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06363734
What this trial is testing

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Who this might be right for
Non-small Cell Lung CancerEGFR Activating MutationCell Cycle Deregulation+1 more
Tianjin Medical University Cancer Institute and Hospital 32
Not applicableWithdrawnNCT02368990
What this trial is testing

T790M Mutation Positive 2nd Line STandard of cAre Registry

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca
Testing effectiveness (Phase 2)Ended earlyNCT02122003
What this trial is testing

Second Line Sorafenib After Pazopanib in Patients With RCC

Who this might be right for
Metastatic Renal Cell Carcinoma
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 16
Testing effectiveness (Phase 2)Active Not RecruitingNCT05078931
What this trial is testing

Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients

Who this might be right for
NSCLC
Shanghai Chest Hospital 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944772
What this trial is testing

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 247
Not applicableUnknownNCT03532698
What this trial is testing

Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer Stage IIIBNon-small Cell Lung Cancer Stage IVEGFR T790M
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 100
Not applicableUnknownNCT02738593
What this trial is testing

Detection Cell Free DNA in Lung Cancer Patients

Who this might be right for
Non-small Cell Lung Cancer
Sun Yat-sen University 124
Not applicableLooking for participantsNCT05598528
What this trial is testing

Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)

Who this might be right for
Lung Cancer, Non-small CellEGFR Gene MutationEGFR-TKI Resistant Mutation+2 more
Second Xiangya Hospital of Central South University 210
Not applicableEnded earlyNCT03053297
What this trial is testing

Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
AstraZeneca 89
Early research (Phase 1)Active Not RecruitingNCT02609776
What this trial is testing

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non-Small-Cell Lung Cancer
Janssen Research & Development, LLC 751
Not applicableUnknownNCT01776684
What this trial is testing

Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

Who this might be right for
EGFR Mutation Positive Non-small Cell Lung Cancer
Samsung Medical Center 200
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06818955
What this trial is testing

Orlistat Overcoming Third-generation EGFR-TKI Resistance

Who this might be right for
Lung AdenocarcinomaOsimertinib
Ping Peng 36
Not applicableStudy completedNCT04965649
What this trial is testing

Is There an Association Between Innate CD8+ T Cells and the Evolution of Tyrosine Kinase Inhibitor Resistance Mutations in Phi+ Hematological Malignancies.

Who this might be right for
LeukemiaMyelogenous LeukemiaChronic Leukemia+1 more
Centre Hospitalier Universitaire de Nīmes 30
Testing effectiveness (Phase 2)UnknownNCT01861223
What this trial is testing

Afatinib Plus Nimotuzumb for NSCLC

Who this might be right for
NSCLC
Samsung Medical Center 50
Testing effectiveness (Phase 2)Looking for participantsNCT06706076
What this trial is testing

BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)
BlossomHill Therapeutics 675
Testing effectiveness (Phase 2)UnknownNCT05178511
What this trial is testing

Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance

Who this might be right for
The Diagnosis Was ALK Positive NSCLCSecond Generation ALK-TKI is ResistantEfficacy of Ensatinib in This Subset of Patients
Li Zhang, MD 40
Testing effectiveness (Phase 2)Study completedNCT01718847
What this trial is testing

NOV120101 Phase 2 Study in NSCLC Patients With Aquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors

Who this might be right for
Increased Drug Resistance
National OncoVenture 40
Large-scale testing (Phase 3)UnknownNCT03428022
What this trial is testing

Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC

Who this might be right for
NSCLCApatinibEGFR-TKI
Shenzhen People's Hospital 54
Large-scale testing (Phase 3)Not Yet RecruitingNCT07489755
What this trial is testing

TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients

Who this might be right for
Chronic Myelogenous LeukemiaChronic Myelogenous Leukemia - Chronic Phase
Shenzhen TargetRx Co., Ltd. 180
Testing effectiveness (Phase 2)UnknownNCT03123484
What this trial is testing

Β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC

Who this might be right for
Non Small Cell Lung Cancer
China Medical University, China 80
Next Page